Nasdaq
$1.12▼ 2.61%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.7MShares out 2.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 2d agoAfter-hours26.10.23 07:33SCHEDULE 13GOwnership#●●●
BioNexus Gene Lab Corp
Fidelion Diagnostics Pte Ltd, Molecule Bio LLC, Rainy Morning Technology (Hong Kong) Limited, and Ling Xiao have filed a joint Schedule 13G regarding their common stock holdings in BioNexus Gene Lab Corp. This filing formalizes the joint ownership of the company's shares by these entities and the individual.…more
$1.12-2.61%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Pre-market26.10.07 22:008-KKey event
BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. (BGLC) has entered into a strategic agreement to secure an exclusive healthcare license for the CogniAI platform in Malaysia from Ruanyun Edai Technology (RYET). BGLC will issue a total of 560,000 common shares to RYET, consisting of 410,000 shares for the license consideration and 150,000 shares for a reciprocal equity investment. The transaction is subject to closing conditions and must be completed by March 31, 2027, as BGLC aims to target Malaysia's public healthcare digitalization initiatives.…more
$1.12-2.61%vs prev closeView filingShare - 8.7After-hours26.08.08 05:283Ownership
BioNexus Gene Lab Corp
BioNexus Gene Lab Corp(BGLC)의 주요 주주인 FIDELION DIAGNOSTICS PTE. LTD.가 2025년 11월 28일 기준으로 신규 지분 보유 현황을 보고하는 Form 3를 제출했다. 이는 해당 법인이 회사의 지분을 보유한 주요 주주로서 SEC에 공식적으로 보고 의무를 이행한 것이다.…more
$1.12-2.61%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 21:30#●●●#●●●#●●●
BioNexus to Build AI Applications for Malaysian Healthcare
BioNexus Gene Lab has signed an exclusive license agreement to utilize the CogniAI platform for Malaysia's public healthcare digitalization initiatives. However, the company has not yet secured any government contracts, and the deal involves share issuance as payment.…more
$1.12-2.61%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 7.28Pre-market26.07.28 22:00
●●●●●●●● ●●●●● ●●●●●●
바이오넥서스가 중국 현지 방문을 통해 암 진단 플랫폼 '비타가드'의 동남아시아 시장 진출을 위한 기술 및 운영 준비를 본격화했습니다. 이번 협력을 통해 동남아 시장 내 정밀 의료 사업을 확대하고 향후 지속적인 검사 수요를 확보할 것으로 기대됩니다.…more
$1.12-2.61%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report